Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells Journal Article
| Authors: | Fay, J. W.; Palucka, A. K.; Paczesny, S.; Dhodapkar, M.; Johnston, D. A.; Burkeholder, S.; Ueno, H.; Banchereau, J. |
| Article Title: | Long-term outcomes in patients with metastatic melanoma vaccinated with melanoma peptide-pulsed CD34+ progenitor-derived dendritic cells |
| Abstract: | Between March 1999 and May 2000, 18 HLA-A*0201+ patients with metastatic melanoma were enrolled in a phase I trial using a dendritic cell (DC) vaccine generated by culturing CD34+ hematopoietic progenitors. This vaccine includes Langerhans cells. The DC vaccine was loaded with four melanoma peptides (MART-1/MelanA, tyrosinase, MAGE-3, and gp100), Influenza matrix peptide (Flu-MP), and keyhole limpet hemocyanin (KLH). Ten patients received eight vaccinations, one patient received six vaccinations, one patient received five vaccinations, and six patients received four vaccinations. Peptide-specific immunity was measured by IFN-γ production and tetramer staining in blood mononuclear cells. The estimated median overall survival was 20 months (range: 2-83), and the median event-free survival was 7 months (range: 2-83). As of August 2005, four patients are alive (three patients had M1a disease and one patient had M1c disease). Three of them have had no additional therapy since trial completion; two of them had solitary lymph node metastasis, and one patient had liver metastasis. Patients who survived longer were those who mounted melanoma peptide-specific immunity to at least two melanoma peptides. The present results therefore justify the design of larger follow-up studies to assess the immunological and clinical outcomes in patients with metastatic melanoma vaccinated with peptide-pulsed CD34-derived DCs. © Springer-Verlag 2005. |
| Keywords: | adult; cancer survival; clinical article; treatment outcome; aged; middle aged; survival analysis; unclassified drug; clinical trial; flow cytometry; lymph node metastasis; cd8-positive t-lymphocytes; cd34 antigen; dendritic cell vaccine; glycoprotein gp 100; melanoma; metastasis; dendritic cell; neoplasm proteins; peptide; time; liver metastasis; lymphocyte activation; dendritic cells; mononuclear cell; antigens, neoplasm; gamma interferon; cell culture; cancer vaccines; membrane glycoproteins; melanoma antigen 3; vaccination; stem cells; melan a; hematopoietic stem cell; monophenol monooxygenase; recombinant granulocyte colony stimulating factor; hla a antigen; antigens, cd34; keyhole limpet hemocyanin; langerhans cell; interferon type ii; interferon production; influenza matrix peptide; melanoma peptide |
| Journal Title: | Cancer Immunology, Immunotherapy |
| Volume: | 55 |
| Issue: | 10 |
| ISSN: | 0340-7004 |
| Publisher: | Springer |
| Date Published: | 2006-10-01 |
| Start Page: | 1209 |
| End Page: | 1218 |
| Language: | English |
| DOI: | 10.1007/s00262-005-0106-6 |
| PUBMED: | 16331519 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Cited By (since 1996): 63" - "Export Date: 4 June 2012" - "CODEN: CIIMD" - "Source: Scopus" |
